Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$10.76 +4.2%	$9.54	$7.08 ▼ $20.60	$220.95M	1.38	74,188 shs	76,636 shs
ANNX Annexon	$1.86 -2.1%	$2.13	$1.29 ▼ $7.85	$204.07M	1.24	1.81 million shs	1.60 million shs
CRGX CARGO Therapeutics	$4.57 +0.7%	$4.16	$3.00 ▼ $25.45	$210.46M	0.66	513,571 shs	1.27 million shs
DTIL Precision BioSciences	$5.64 +7.8%	$5.03	$3.61 ▼ $13.44	$59.50M	1.59	181,418 shs	137,975 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	+0.10%	-1.24%	+17.33%	-8.58%	-41.11%
ANNX Annexon	+0.53%	+7.95%	-15.56%	-53.88%	-59.57%
CRGX CARGO Therapeutics	-1.94%	-1.30%	+8.61%	-65.58%	-76.18%
DTIL Precision BioSciences	+2.35%	-1.69%	+11.28%	+6.52%	-46.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.6481 of 5 stars	1.0	4.0	0.0	3.3	0.0	0.0
ANNX Annexon	2.0276 of 5 stars	3.5	1.0	0.0	2.7	1.7	0.6
CRGX CARGO Therapeutics	3.0252 of 5 stars	3.9	0.0	0.0	2.7	1.7	1.3
DTIL Precision BioSciences	4.265 of 5 stars	3.5	3.0	4.6	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	2.00	Hold	$7.00	-34.94% Downside
ANNX Annexon	3.00	Buy	$18.67	903.58% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	228.23% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	733.33% Upside

Current Analyst Ratings Breakdown

Latest DTIL, CRGX, AMRN, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $7.00
3/28/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/19/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/4/2025	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
2/19/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
1/30/2025	CRGX CARGO Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/30/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$32.00 ➝ $3.00
1/30/2025	CRGX CARGO Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$34.00 ➝ $4.00
1/30/2025	CRGX CARGO Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
1/30/2025	CRGX CARGO Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Underweight
1/30/2025	CRGX CARGO Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$32.00 ➝ $7.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$228.61M	0.97	N/A	N/A	$1.35 per share	7.97
ANNX Annexon	N/A	N/A	N/A	N/A	$3.20 per share	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$9.84 per share	N/A
DTIL Precision BioSciences	$68.70M	0.87	N/A	N/A	$4.53 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$59.11M	-$4.00	N/A	N/A	N/A	-16.33%	-7.22%	-4.96%	5/7/2025 (Estimated)
ANNX Annexon	-$134.24M	-$1.02	N/A	N/A	N/A	N/A	-38.99%	-33.90%	5/12/2025 (Estimated)
CRGX CARGO Therapeutics	-$98.15M	-$3.72	N/A	N/A	N/A	N/A	-38.16%	-33.94%	5/13/2025 (Estimated)
DTIL Precision BioSciences	-$61.32M	$1.90	94.02	N/A	N/A	11.48%	-23.69%	-6.98%	5/12/2025 (Estimated)

Latest DTIL, CRGX, AMRN, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CRGX CARGO Therapeutics	-$0.70	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	ANNX Annexon	-$0.30	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	DTIL Precision BioSciences	-$0.38	N/A	N/A	N/A	$5.00 million	N/A
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	N/A	N/A	N/A	$50.75 million	N/A
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million
3/12/2025	Q4 2024	AMRN Amarin	-$1.20	-$2.40	-$1.20	-$0.12	$32.37 million	$62.31 million
3/3/2025	Q4 2024	ANNX Annexon	-$0.28	-$0.33	-$0.05	-$0.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.23	2.11
ANNX Annexon	N/A	17.17	17.18
CRGX CARGO Therapeutics	N/A	18.94	18.95
DTIL Precision BioSciences	0.34	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
ANNX Annexon	N/A
CRGX CARGO Therapeutics	93.16%
DTIL Precision BioSciences	37.99%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	1.96%
ANNX Annexon	12.67%
CRGX CARGO Therapeutics	1.38%
DTIL Precision BioSciences	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	20.53 million	402.62 million	Optionable
ANNX Annexon	60	109.71 million	93.09 million	Optionable
CRGX CARGO Therapeutics	116	46.05 million	45.39 million	N/A
DTIL Precision BioSciences	200	10.55 million	7.36 million	No Data

DTIL, CRGX, AMRN, and ANNX Headlines

Recent News About These Companies

Lynx1 Capital Management LP Makes New Investment in Precision BioSciences, Inc. (NASDAQ:DTIL)

April 29 at 7:00 AM | marketbeat.com

Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Update

April 22, 2025 | marketbeat.com

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

April 16, 2025 | zacks.com

Precision Medicine Group Appoints Chief Information and Technology Officer

April 16, 2025 | contractpharma.com

Precision BioSciences stock rises following FDA Fast Track designation

April 15, 2025 | in.investing.com

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

April 15, 2025 | businesswire.com

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025 | businesswire.com

Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys 3,250 Shares of Stock

March 28, 2025 | insidertrades.com

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

March 26, 2025 | zacks.com

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

March 26, 2025 | businesswire.com

Assessing Precision BioSciences: Insights From 4 Financial Analysts

March 21, 2025 | nasdaq.com

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

March 21, 2025 | businesswire.com

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

March 20, 2025 | businesswire.com

Precision BioSciences presents preclinical data from PBGENE-DMD program

March 19, 2025 | markets.businessinsider.com

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 19, 2025 | businesswire.com

Precision BioSciences Nets FDA Clearance to Start Hepatitis B Gene-Editing Drug Trial

March 18, 2025 | precisionmedicineonline.com

FDA clears Precision BioSciences’ IND for PBGENE-HBV to treat HBV

March 17, 2025 | markets.businessinsider.com

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

March 17, 2025 | businesswire.com

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel

March 15, 2025 | seekingalpha.com

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

February 24, 2025 | businesswire.com

H.C. Wainwright Maintains Buy on Precision BioSciences Stock

February 21, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, CRGX, AMRN, and ANNX Company Descriptions

Amarin NASDAQ:AMRN

$10.76 +0.43 (+4.16%)

As of 04:00 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Annexon NASDAQ:ANNX

$1.86 -0.04 (-2.11%)

As of 04:00 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

CARGO Therapeutics NASDAQ:CRGX

$4.57 +0.03 (+0.66%)

As of 04:00 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Precision BioSciences NASDAQ:DTIL

$5.64 +0.41 (+7.84%)

As of 04:00 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time